Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
3 SIGMAR1 [2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
4 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
5 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
6 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
7 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
8 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
9 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
10 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
11 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
12 TUBB3 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
13 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
14 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
15 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
16 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
17 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
18 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
19 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
20 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
21 TUBB4A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
22 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
23 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
24 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
25 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
26 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
27 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
28 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
29 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
30 TUBB4B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
31 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D00529 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
32 CYSLTR1 [2] Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
33 HRH3 [1] Neuroactive ligand-receptor interaction D09870 Bavisant [1] 6
34 HRH3 [1] Neuroactive ligand-receptor interaction D10749 Pitolisant [3] 6, 113, 193
35 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
36 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
37 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
38 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
39 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
40 CHRM1 [8] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
41 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide [3] 6, 13, 19
42 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
43 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00525 Pilocarpine [3] 6, 53, 299
44 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00722 Oxybutynin [3] 6, 13, 53
45 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
46 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D02200 Pilocarpine [3] 6, 53, 299
47 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D02212 Ipratropium [2] 6, 86
48 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D05478 Pilocarpine [3] 6, 53, 299
49 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D07226 Fesoterodine [1] 6
50 CHRM2 [6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
51 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
52 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
53 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00525 Pilocarpine [3] 6, 53, 299
54 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
55 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
56 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01269 Solifenacin [3] 6, 13, 53
57 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01699 Darifenacin [2] 6, 13
58 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02200 Pilocarpine [3] 6, 53, 299
59 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
60 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin [2] 6, 13
61 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D05478 Pilocarpine [3] 6, 53, 299
62 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D07226 Fesoterodine [1] 6
63 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin [3] 6, 13, 53
64 CHRM3 [11] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
65 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide [3] 6, 13, 19
66 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
67 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00722 Oxybutynin [3] 6, 13, 53
68 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00787 Trihexyphenidyl [2] 5, 6
69 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D02212 Ipratropium [2] 6, 86
70 CHRM4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
71 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [3] 6, 13, 19
72 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
73 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin [3] 6, 13, 53
74 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00787 Trihexyphenidyl [2] 5, 6
75 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D02212 Ipratropium [2] 6, 86
76 CHRM5 [6] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
77 CHRNA1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
78 CHRNA1 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
79 CHRNA1 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
80 CHRNA2 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
81 CHRNA2 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
82 CHRNA2 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
83 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
84 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
85 CHRNA3 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
86 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
87 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
88 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
89 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [2] 6, 18
90 CHRNA5 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
91 CHRNA5 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
92 CHRNA5 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
93 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
94 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
95 CHRNA7 [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
96 CHRNB1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
97 CHRNB1 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
98 CHRNB1 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
99 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
100 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
101 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
102 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [2] 6, 18
103 CHRNB3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
104 CHRNB3 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
105 CHRNB3 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
106 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
107 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
108 CHRNB4 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
109 CHRND [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
110 CHRND [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
111 CHRND [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
112 CHRNE [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
113 CHRNE [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
114 CHRNE [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
115 CHRNG [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
116 CHRNG [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
117 CHRNG [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
118 CLCN2 [1] Mineral absorption D04790 Lubiprostone [4] 6, 13, 290, 299
119 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05099 Nabilone [2] 6, 13
120 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol [19] 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
121 CNR2 [1] Neuroactive ligand-receptor interaction D05099 Nabilone [2] 6, 13
122 CNR2 [1] Neuroactive ligand-receptor interaction D10915 Cannabidiol [18] 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
123 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00781 Entacapone [2] 6, 17
124 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00786 Tolcapone [3] 6, 28, 127
125 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D10825 Opicapone [1] 6
126 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
127 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
128 ADORA2A [3] Rap1 signaling pathway, Vascular smooth muscle contraction, Parkinson disease D00045 Adenosine [3] 13, 58, 65
129 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
130 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
131 ADORA2A [3] Rap1 signaling pathway, Vascular smooth muscle contraction, Parkinson disease D02017 Theophylline [2] 236, 299
132 ADORA2A [3] Rap1 signaling pathway, Vascular smooth muscle contraction, Parkinson disease D02769 Adenosine phosphate [1] 46
133 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D04641 Istradefylline [1] 6
134 ADORA2A [3] Rap1 signaling pathway, Vascular smooth muscle contraction, Parkinson disease D05711 Regadenoson [1] 58
135 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D09717 Preladenant [1] 6
136 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D10174 Tozadenant [1] 6
137 CSF2RA [4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D05803 Sargramostim [7] 6, 28, 60, 62, 96, 229, 285
138 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim [34] 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
139 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
140 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
141 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
142 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
143 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
144 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
145 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
146 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
147 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
148 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
149 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
150 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
151 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
152 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
153 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
154 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
155 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
156 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
157 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
158 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
159 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
160 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
161 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
162 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
163 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
164 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
165 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
166 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
167 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
168 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
169 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
170 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
171 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
172 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
173 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
174 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
175 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
176 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
177 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
178 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
179 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
180 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
181 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
182 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
183 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
184 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
185 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
186 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
187 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
188 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
189 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
190 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
191 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
192 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
193 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
194 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00255 Carvedilol [5] 6, 57, 86, 113, 210
195 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol [1] 6
196 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
197 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa [5] 5, 6, 17, 169, 170
198 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin [1] 6
199 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03415 Carvedilol [5] 6, 57, 86, 113, 210
200 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
201 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00255 Carvedilol [5] 6, 57, 86, 113, 210
202 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol [1] 6
203 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
204 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
205 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol [1] 6
206 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
207 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D03415 Carvedilol [5] 6, 57, 86, 113, 210
208 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol [5] 1, 2, 6, 13, 256
209 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
210 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
211 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
212 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
213 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
214 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron [4] 6, 13, 53, 226
215 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril [8] 6, 17, 46, 86, 96, 97, 107, 271
216 DDC [9] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D00558 Carbidopa [9] 2, 4, 6, 13, 17, 90, 140, 164, 201
217 DDC [9] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D03082 Benserazide [1] 6
218 HTR3C [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
219 HTR3C [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [4] 6, 97, 107, 231
220 HTR3C [2] Serotonergic synapse, Taste transduction D00678 Ondansetron [4] 6, 97, 107, 231
221 HTR3C [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
222 NQO1 [7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D00564 Warfarin [13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
223 NQO1 [7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D01280 Warfarin [13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
224 NQO1 [7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D08682 Warfarin [13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
225 DPP4 [1] Protein digestion and absorption D08516 Sitagliptin [4] 6, 75, 233, 299
226 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
227 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D00502 Pergolide [1] 6
228 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D00633 Dopamine [4] 6, 7, 74, 299
229 DRD1 [1] Parkinson disease D01044 Flupentixol [1] 97
230 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D02004 Apomorphine [3] 5, 6, 7
231 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D07460 Apomorphine [3] 5, 6, 7
232 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D07870 Dopamine [4] 6, 7, 74, 299
233 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D08339 Pergolide [1] 6
234 DRD1 [1] Parkinson disease D09886 Dexpramipexole [1] 2
235 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D11431 Tavapadon [1] 6
236 DRD1 [10] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D11839 Foslevodopa [1] 6
237 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
238 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00136 Haloperidol [1] 8
239 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00270 Chlorpromazine [1] 254
240 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00426 Risperidone [5] 8, 156, 179, 187, 206
241 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00454 Olanzapine [2] 2, 8
242 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00458 Quetiapine [2] 6, 13
243 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00502 Pergolide [1] 6
244 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00559 Pramipexole [3] 2, 6, 20
245 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00560 Pimozide [1] 2
246 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00633 Dopamine [4] 6, 7, 74, 299
247 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00702 Buspirone [3] 6, 51, 179
248 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00726 Metoclopramide [1] 51
249 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00780 Bromocriptine [2] 6, 74
250 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00784 Ropinirole [4] 2, 6, 74, 309
251 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00789 Chlorpromazine [1] 254
252 DRD2 [2] Rap1 signaling pathway, Parkinson disease D00799 Trifluoperazine [2] 283, 284
253 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00987 Cabergoline [3] 6, 74, 75
254 DRD2 [2] Rap1 signaling pathway, Parkinson disease D01044 Flupentixol [1] 97
255 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01164 Aripiprazole [2] 6, 206
256 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01226 Sulpiride [5] 2, 6, 17, 46, 70
257 DRD2 [2] Rap1 signaling pathway, Parkinson disease D01348 Terguride [2] 51, 86
258 DRD2 [2] Rap1 signaling pathway, Parkinson disease D01448 Trifluoperazine [2] 283, 284
259 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01462 Lisuride [2] 6, 86
260 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01745 Domperidone [5] 6, 13, 17, 51, 230
261 DRD2 [2] Rap1 signaling pathway, Parkinson disease D01898 Haloperidol [1] 8
262 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D02004 Apomorphine [3] 5, 6, 7
263 DRD2 [2] Rap1 signaling pathway, Parkinson disease D02213 Metoclopramide [1] 51
264 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D03165 Bromocriptine [2] 6, 74
265 DRD2 [2] Rap1 signaling pathway, Parkinson disease D03274 Chlorpromazine [1] 254
266 DRD2 [2] Rap1 signaling pathway, Parkinson disease D04034 Chlorpromazine [1] 254
267 DRD2 [2] Rap1 signaling pathway, Parkinson disease D05008 Metoclopramide [1] 51
268 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D05575 Pramipexole [3] 2, 6, 20
269 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D05768 Rotigotine [2] 6, 127
270 DRD2 [2] Rap1 signaling pathway, Parkinson disease D06623 Olanzapine [2] 2, 8
271 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07305 Piribedil [1] 6
272 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07309 Melperone [1] 6
273 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07460 Apomorphine [3] 5, 6, 7
274 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07593 Buspirone [3] 6, 51, 179
275 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07868 Domperidone [5] 6, 13, 17, 51, 230
276 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07870 Dopamine [4] 6, 7, 74, 299
277 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08132 Lisuride [2] 6, 86
278 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08339 Pergolide [1] 6
279 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08456 Quetiapine [2] 6, 13
280 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08489 Ropinirole [4] 2, 6, 74, 309
281 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08549 Sulpiride [5] 2, 6, 17, 46, 70
282 DRD2 [2] Rap1 signaling pathway, Parkinson disease D08590 Tiapride [1] 8
283 DRD2 [2] Rap1 signaling pathway, Parkinson disease D08636 Trifluoperazine [2] 283, 284
284 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D09397 Pardoprunox [1] 6
285 DRD2 [2] Rap1 signaling pathway, Parkinson disease D09886 Dexpramipexole [1] 2
286 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D09953 Pridopidine [3] 2, 6, 8
287 DRD2 [2] Rap1 signaling pathway, Parkinson disease D09997 Cariprazine [1] 21
288 DRD2 [8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D11839 Foslevodopa [1] 6
289 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
290 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole [3] 2, 6, 20
291 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
292 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole [4] 2, 6, 74, 309
293 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01164 Aripiprazole [2] 6, 206
294 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01462 Lisuride [2] 6, 86
295 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
296 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07305 Piribedil [1] 6
297 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
298 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
299 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
300 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09397 Pardoprunox [1] 6
301 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
302 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
303 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00283 Clozapine [1] 6
304 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole [3] 2, 6, 20
305 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
306 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole [4] 2, 6, 74, 309
307 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01462 Lisuride [2] 6, 86
308 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
309 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
310 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
311 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
312 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
313 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
314 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
315 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
316 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D11431 Tavapadon [1] 6
317 DRD5 [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
318 ABAT [7] Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
319 HTR3D [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
320 HTR3D [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [4] 6, 97, 107, 231
321 HTR3D [2] Serotonergic synapse, Taste transduction D00678 Ondansetron [4] 6, 97, 107, 231
322 HTR3D [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
323 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
324 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
325 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
326 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
327 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
328 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
329 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
330 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
331 TUBB [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
332 EPOR [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin [10] 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
333 F8 [1] Complement and coagulation cascades D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
334 F8 [1] Complement and coagulation cascades D02235 Desmopressin [6] 6, 64, 72, 75, 225, 288
335 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
336 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06378 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
337 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06379 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
338 FDPS [4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid [13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
339 MTOR [51] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus [41] 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
340 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
341 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
342 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00548 Etomidate [1] 6
343 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
344 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
345 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
346 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
347 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
348 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
349 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
350 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
351 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
352 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
353 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
354 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
355 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
356 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
357 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
358 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
359 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
360 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
361 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
362 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
363 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
364 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
365 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
366 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
367 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
368 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
369 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
370 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
371 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
372 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
373 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
374 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
375 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
376 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
377 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
378 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
379 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
380 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
381 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
382 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
383 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
384 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
385 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
386 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
387 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
388 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
389 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
390 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
391 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
392 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
393 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
394 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
395 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
396 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
397 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
398 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
399 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
400 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
401 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
402 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
403 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
404 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
405 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
406 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
407 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
408 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
409 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
410 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
411 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
412 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
413 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
414 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
415 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
416 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
417 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
418 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
419 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
420 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
421 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
422 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
423 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
424 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
425 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
426 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
427 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
428 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
429 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
430 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
431 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
432 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
433 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
434 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
435 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
436 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
437 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
438 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
439 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
440 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
441 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
442 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
443 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
444 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
445 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
446 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
447 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
448 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
449 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
450 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
451 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
452 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
453 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
454 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
455 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
456 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
457 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
458 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
459 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
460 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
461 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
462 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
463 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
464 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
465 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
466 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
467 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
468 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
469 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
470 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
471 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
472 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
473 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
474 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
475 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
476 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
477 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
478 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
479 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
480 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
481 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
482 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
483 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
484 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
485 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
486 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
487 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
488 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
489 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
490 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
491 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
492 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
493 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
494 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
495 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
496 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
497 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
498 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
499 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
500 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
501 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
502 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
503 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
504 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
505 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
506 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
507 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
508 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
509 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
510 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
511 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
512 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
513 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
514 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
515 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
516 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
517 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
518 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
519 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
520 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
521 GAD1 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
522 GAD2 [7] Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
523 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08953 Nilotinib [5] 6, 8, 34, 51, 86
524 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D09664 Saracatinib [3] 6, 89, 272
525 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D04121 Exenatide [6] 6, 17, 72, 78, 193, 233
526 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D06404 Liraglutide [3] 6, 75, 193
527 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D09729 Lixisenatide [1] 6
528 GLP1R [3] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D10025 Semaglutide [1] 6
529 HTR3E [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
530 HTR3E [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [4] 6, 97, 107, 231
531 HTR3E [2] Serotonergic synapse, Taste transduction D00678 Ondansetron [4] 6, 97, 107, 231
532 HTR3E [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
533 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
534 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
535 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
536 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
537 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
538 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
539 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
540 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
541 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
542 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
543 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
544 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
545 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
546 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
547 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
548 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
549 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
550 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
551 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00777 Amantadine [4] 6, 8, 13, 127
552 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
553 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D02780 Acamprosate [2] 6, 206
554 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
555 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
556 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
557 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07058 Acamprosate [2] 6, 206
558 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine [4] 6, 8, 13, 127
559 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
560 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
561 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
562 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
563 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
564 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
565 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
566 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
567 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
568 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
569 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
570 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
571 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
572 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
573 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
574 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
575 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
576 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
577 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
578 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
579 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
580 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
581 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
582 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
583 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
584 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00777 Amantadine [4] 6, 8, 13, 127
585 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
586 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D02780 Acamprosate [2] 6, 206
587 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
588 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
589 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
590 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07058 Acamprosate [2] 6, 206
591 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine [4] 6, 8, 13, 127
592 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
593 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
594 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
595 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00777 Amantadine [4] 6, 8, 13, 127
596 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
597 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D02780 Acamprosate [2] 6, 206
598 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
599 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
600 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
601 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07058 Acamprosate [2] 6, 206
602 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine [4] 6, 8, 13, 127
603 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
604 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
605 NR3C1 [1] Neuroactive ligand-receptor interaction D00088 Hydrocortisone [11] 6, 41, 46, 53, 75, 78, 81, 83, 97, 98, 299
606 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [47] 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
607 NR3C1 [1] Neuroactive ligand-receptor interaction D00473 Prednisone [47] 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
608 NR3C1 [1] Neuroactive ligand-receptor interaction D00751 Methylprednisolone [47] 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
609 NR3C1 [1] Neuroactive ligand-receptor interaction D00976 Hydrocortisone cypionate [3] 6, 81, 83
610 NR3C1 [1] Neuroactive ligand-receptor interaction D00979 Methylprednisolone [47] 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
611 NR3C1 [1] Neuroactive ligand-receptor interaction D01442 Hydrocortisone succinate [3] 6, 81, 83
612 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone [47] 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
613 NR3C1 [1] Neuroactive ligand-receptor interaction D05001 Methylprednisolone [47] 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
614 NR3C1 [1] Neuroactive ligand-receptor interaction D05002 Methylprednisolone [47] 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
615 GUCY2C [2] Purine metabolism, Metabolic pathways D09355 Linaclotide [2] 6, 97
616 HCRTR1 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [2] 6, 13
617 HCRTR2 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [2] 6, 13
618 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00359 Lovastatin [11] 6, 34, 46, 79, 156, 160, 195, 206, 263, 280, 310
619 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00434 Simvastatin [21] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
620 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D01915 Rosuvastatin [11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
621 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08492 Rosuvastatin [11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
622 HPD [5] Ubiquinone and other terpenoid-quinone biosynthesis, Tyrosine metabolism, Phenylalanine metabolism, Metabolic pathways, Biosynthesis of cofactors D05177 Nitisinone [3] 6, 164, 241
623 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00814 Doxepin [1] 6
624 HRH1 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07875 Doxepin [1] 6
625 HRH2 [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00318 Famotidine [7] 6, 46, 61, 86, 98, 107, 300
626 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00702 Buspirone [3] 6, 51, 179
627 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D01164 Aripiprazole [2] 6, 206
628 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D07593 Buspirone [3] 6, 51, 179
629 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D09397 Pardoprunox [1] 6
630 HTR1A [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
631 HTR1B [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
632 HTR1D [4] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
633 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00283 Clozapine [1] 6
634 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00458 Quetiapine [2] 6, 13
635 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D01164 Aripiprazole [2] 6, 206
636 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08456 Quetiapine [2] 6, 13
637 HTR2A [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D09645 Nelotanserin [1] 6
638 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00283 Clozapine [1] 6
639 HTR2C [5] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02578 Agomelatine [1] 6
640 HTR3A [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
641 HTR3A [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [4] 6, 97, 107, 231
642 HTR3A [2] Serotonergic synapse, Taste transduction D00678 Ondansetron [4] 6, 97, 107, 231
643 HTR3A [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
644 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
645 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
646 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
647 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
648 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
649 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
650 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
651 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
652 TUBB8 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
653 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
654 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
655 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
656 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
657 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
658 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
659 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
660 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
661 TUBB2B [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
662 KCNA4 [2] Cortisol synthesis and secretion, Cushing syndrome D04127 Dalfampridine [5] 3, 4, 6, 13, 14
663 KCNC3 [1] Spinocerebellar ataxia D04127 Dalfampridine [3] 6, 13, 14
664 KCND2 [1] Serotonergic synapse D04127 Dalfampridine [3] 6, 13, 14
665 KCND3 [1] Spinocerebellar ataxia D04127 Dalfampridine [3] 6, 13, 14
666 KCNJ11 [3] Insulin secretion, GnRH secretion, Type II diabetes mellitus D00594 Repaglinide [3] 6, 21, 299
667 KIT [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
668 KIT [11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib [6] 2, 5, 6, 13, 46, 96
669 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D00505 Phenelzine [1] 6
670 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02561 Moclobemide [1] 6
671 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02579 Iproniazid [1] 6
672 MAOA [5] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Serotonergic synapse, Parkinson disease D05458 Phentermine [1] 97
673 MAOA [5] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Serotonergic synapse, Parkinson disease D05459 Phentermine [1] 97
674 MAOA [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08349 Phenelzine [1] 6
675 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D00505 Phenelzine [1] 6
676 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D00785 Selegiline [1] 6
677 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02562 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
678 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02579 Iproniazid [1] 6
679 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D03731 Selegiline [1] 6
680 MAOB [5] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Serotonergic synapse, Parkinson disease D05458 Phentermine [1] 97
681 MAOB [5] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Serotonergic synapse, Parkinson disease D05459 Phentermine [1] 97
682 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08349 Phenelzine [1] 6
683 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08469 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
684 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10158 Safinamide [2] 6, 17
685 MAOB [14] Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10829 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
686 MAPT [2] Parkinson disease, Pathways of neurodegeneration - multiple diseases D11210 Flortaucipir [3] 5, 7, 127
687 MAPT [2] Parkinson disease, Pathways of neurodegeneration - multiple diseases D11293 Gosuranemab [1] 5
688 MAP3K5 [9] Platinum drug resistance, Sphingolipid signaling pathway, Protein processing in endoplasmic reticulum, Tight junction, TNF signaling pathway, Thermogenesis, Parkinson disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases D10988 Selonsertib [1] 86
689 NR3C2 [1] Aldosterone-regulated sodium reabsorption D00986 Fludrocortisone [3] 6, 17, 81
690 NR3C2 [1] Aldosterone-regulated sodium reabsorption D07967 Fludrocortisone [3] 6, 17, 81
691 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D00487 Pyridostigmine [4] 3, 6, 11, 256
692 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D00670 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
693 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D02173 Galantamine [2] 6, 127
694 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D02558 Rivastigmine [3] 5, 6, 13
695 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine [3] 5, 6, 13
696 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D04292 Galantamine [2] 6, 127
697 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
698 MTNR1A [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02578 Agomelatine [1] 6
699 MTNR1A [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon [3] 6, 8, 46
700 MTNR1A [2] Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
701 MTNR1B [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02578 Agomelatine [1] 6
702 MTNR1B [2] Neuroactive ligand-receptor interaction, Circadian entrainment D02689 Ramelteon [3] 6, 8, 46
703 MTNR1B [2] Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
704 NFE2L2 [3] Protein processing in endoplasmic reticulum, Parkinson disease, Pathways in cancer D10964 Omaveloxolone [1] 18
705 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
706 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
707 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
708 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
709 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
710 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
711 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
712 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
713 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D01340 Naloxone [2] 6, 226
714 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
715 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
716 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
717 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
718 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
719 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
720 OPRD1 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
721 OPRK1 [1] Neuroactive ligand-receptor interaction D01340 Naloxone [2] 6, 226
722 OPRK1 [1] Neuroactive ligand-receptor interaction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
723 OPRK1 [1] Neuroactive ligand-receptor interaction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
724 OPRK1 [1] Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
725 OPRK1 [1] Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
726 OPRK1 [1] Neuroactive ligand-receptor interaction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
727 OPRK1 [1] Neuroactive ligand-receptor interaction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
728 OPRK1 [1] Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
729 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01177 Remifentanil [2] 6, 70
730 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01340 Naloxone [2] 6, 226
731 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D02095 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
732 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D03783 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
733 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05111 Nalmefene [1] 6
734 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
735 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05312 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
736 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05462 Oxycodone [7] 6, 13, 46, 70, 226, 231, 298
737 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08249 Naloxone [2] 6, 226
738 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08473 Remifentanil [2] 6, 70
739 OXTR [4] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D00089 Oxytocin [6] 6, 72, 127, 193, 206, 226
740 PDE2A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
741 PDE2A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
742 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
743 PDE3A [6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
744 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
745 PDE3B [11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
746 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
747 PDE4A [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
748 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
749 PDE4B [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
750 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
751 PDE4C [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
752 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
753 PDE4D [5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
754 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
755 PDE1B [7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
756 PDGFRA [20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
757 PDGFRB [19] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human papillomavirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08953 Nilotinib [5] 6, 8, 34, 51, 86
758 PPARG [11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00945 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
759 PPARG [11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
760 PPP3CA [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
761 PPP3CA [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
762 PPP3CB [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
763 PPP3CB [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
764 PPP3CC [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
765 PPP3CC [33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
766 PPP3R1 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
767 PPP3R1 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
768 PPP3R2 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
769 PPP3R2 [32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
770 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
771 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D02235 Desmopressin [6] 6, 64, 72, 75, 225, 288
772 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D03365 Nicotine [3] 6, 13, 84
773 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05156 Nicotine [3] 6, 13, 84
774 CHRNA9 [2] Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05157 Nicotine [3] 6, 13, 84
775 PRKAA1 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
776 PRKAA1 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
777 PRKAA2 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
778 PRKAA2 [20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
779 CACNA2D3 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
780 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00280 Clonazepam [1] 6
781 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
782 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00549 Propofol [10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
783 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
784 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
785 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
786 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00706 Zolpidem [3] 5, 6, 46
787 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D01372 Zopiclone [1] 6
788 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
789 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
790 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
791 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
792 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00780 Bromocriptine [2] 6, 74
793 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00987 Cabergoline [3] 6, 74, 75
794 PRL [5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D03165 Bromocriptine [2] 6, 74
795 PSMB5 [5] Proteasome, Parkinson disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D03150 Bortezomib [16] 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
796 PSMB5 [5] Proteasome, Parkinson disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D08880 Carfilzomib [1] 28
797 PSMB5 [5] Proteasome, Parkinson disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D10130 Ixazomib [5] 13, 16, 28, 51, 61
798 CHRNA10 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
799 CHRNA10 [1] Neuroactive ligand-receptor interaction D05156 Nicotine [3] 6, 13, 84
800 CHRNA10 [1] Neuroactive ligand-receptor interaction D05157 Nicotine [3] 6, 13, 84
801 PTGS1 [5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen [18] 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
802 PTGS2 [22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen [18] 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
803 SCN1A [1] Dopaminergic synapse D00358 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
804 SCN1A [1] Dopaminergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
805 SCN1A [1] Dopaminergic synapse D00538 Zonisamide [1] 6
806 SCN1A [1] Dopaminergic synapse D00638 Flecainide [1] 6
807 SCN1A [1] Dopaminergic synapse D01768 Oxybuprocaine [1] 6
808 SCN1A [1] Dopaminergic synapse D02086 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
809 SCN1A [1] Dopaminergic synapse D07962 Flecainide [1] 6
810 SCN1A [1] Dopaminergic synapse D08127 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
811 SCN1A [1] Dopaminergic synapse D08319 Oxybuprocaine [1] 6
812 SCN2A [1] Taste transduction D00358 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
813 SCN2A [1] Taste transduction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
814 SCN2A [1] Taste transduction D00538 Zonisamide [1] 6
815 SCN2A [1] Taste transduction D00638 Flecainide [1] 6
816 SCN2A [1] Taste transduction D01768 Oxybuprocaine [1] 6
817 SCN2A [1] Taste transduction D02086 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
818 SCN2A [1] Taste transduction D07962 Flecainide [1] 6
819 SCN2A [1] Taste transduction D08127 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
820 SCN2A [1] Taste transduction D08319 Oxybuprocaine [1] 6
821 SCN3A [1] Taste transduction D00358 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
822 SCN3A [1] Taste transduction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
823 SCN3A [1] Taste transduction D00538 Zonisamide [1] 6
824 SCN3A [1] Taste transduction D00638 Flecainide [1] 6
825 SCN3A [1] Taste transduction D01768 Oxybuprocaine [1] 6
826 SCN3A [1] Taste transduction D02086 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
827 SCN3A [1] Taste transduction D07962 Flecainide [1] 6
828 SCN3A [1] Taste transduction D08127 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
829 SCN3A [1] Taste transduction D08319 Oxybuprocaine [1] 6
830 SCN5A [1] Adrenergic signaling in cardiomyocytes D00358 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
831 SCN5A [1] Adrenergic signaling in cardiomyocytes D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
832 SCN5A [1] Adrenergic signaling in cardiomyocytes D00538 Zonisamide [1] 6
833 SCN5A [1] Adrenergic signaling in cardiomyocytes D00638 Flecainide [1] 6
834 SCN5A [1] Adrenergic signaling in cardiomyocytes D01768 Oxybuprocaine [1] 6
835 SCN5A [1] Adrenergic signaling in cardiomyocytes D02086 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
836 SCN5A [1] Adrenergic signaling in cardiomyocytes D07962 Flecainide [1] 6
837 SCN5A [1] Adrenergic signaling in cardiomyocytes D08127 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
838 SCN5A [1] Adrenergic signaling in cardiomyocytes D08319 Oxybuprocaine [1] 6
839 SCN9A [1] Taste transduction D00358 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
840 SCN9A [1] Taste transduction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
841 SCN9A [1] Taste transduction D00538 Zonisamide [1] 6
842 SCN9A [1] Taste transduction D00638 Flecainide [1] 6
843 SCN9A [1] Taste transduction D01768 Oxybuprocaine [1] 6
844 SCN9A [1] Taste transduction D02086 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
845 SCN9A [1] Taste transduction D07962 Flecainide [1] 6
846 SCN9A [1] Taste transduction D08127 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
847 SCN9A [1] Taste transduction D08319 Oxybuprocaine [1] 6
848 SLC6A1 [2] Synaptic vesicle cycle, GABAergic synapse D00332 Gabapentin [5] 6, 13, 19, 70, 298
849 SLC6A2 [1] Synaptic vesicle cycle D00814 Doxepin [1] 6
850 SLC6A2 [1] Synaptic vesicle cycle D00816 Nortriptyline [2] 6, 226
851 SLC6A2 [1] Synaptic vesicle cycle D00821 Venlafaxine [3] 6, 13, 46
852 SLC6A2 [1] Synaptic vesicle cycle D01179 Duloxetine [2] 6, 13
853 SLC6A2 [1] Synaptic vesicle cycle D01296 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
854 SLC6A2 [1] Synaptic vesicle cycle D02574 Atomoxetine [4] 6, 8, 13, 17
855 SLC6A2 [1] Synaptic vesicle cycle D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
856 SLC6A2 [1] Synaptic vesicle cycle D07473 Atomoxetine [4] 6, 8, 13, 17
857 SLC6A2 [1] Synaptic vesicle cycle D07875 Doxepin [1] 6
858 SLC6A2 [1] Synaptic vesicle cycle D07880 Duloxetine [2] 6, 13
859 SLC6A2 [1] Synaptic vesicle cycle D08288 Nortriptyline [2] 6, 226
860 SLC6A2 [1] Synaptic vesicle cycle D08670 Venlafaxine [3] 6, 13, 46
861 SLC6A2 [1] Synaptic vesicle cycle D11688 Ampreloxetine [2] 6, 17
862 SLC6A3 [3] Synaptic vesicle cycle, Parkinson disease, Pathways of neurodegeneration - multiple diseases D00817 Bupropion [5] 8, 18, 21, 96, 171
863 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D01296 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
864 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D03215 Armodafinil [3] 6, 13, 84
865 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
866 SLC6A3 [3] Synaptic vesicle cycle, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05458 Phentermine [1] 97
867 SLC6A3 [3] Synaptic vesicle cycle, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05459 Phentermine [1] 97
868 SLC6A3 [3] Synaptic vesicle cycle, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07591 Bupropion [5] 8, 18, 21, 96, 171
869 SLC6A3 [3] Synaptic vesicle cycle, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07938 Bupropion [5] 8, 18, 21, 96, 171
870 SLC6A3 [3] Synaptic vesicle cycle, Parkinson disease, Pathways of neurodegeneration - multiple diseases D08130 Lisdexamfetamine [1] 13
871 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00814 Doxepin [1] 6
872 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00816 Nortriptyline [2] 6, 226
873 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00821 Venlafaxine [3] 6, 13, 46
874 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00822 Citalopram [7] 6, 8, 13, 18, 46, 98, 127
875 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D00825 Sertraline [2] 6, 206
876 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D01179 Duloxetine [2] 6, 13
877 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02260 Paroxetine [4] 6, 13, 46, 85
878 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02360 Sertraline [2] 6, 206
879 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02362 Paroxetine [4] 6, 13, 46, 85
880 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D02567 Escitalopram [3] 2, 6, 13
881 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D05374 Paroxetine [4] 6, 13, 46, 85
882 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D05375 Paroxetine [4] 6, 13, 46, 85
883 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram [7] 6, 8, 13, 18, 46, 98, 127
884 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07704 Escitalopram [3] 2, 6, 13
885 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07875 Doxepin [1] 6
886 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07880 Duloxetine [2] 6, 13
887 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07913 Escitalopram [3] 2, 6, 13
888 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D08288 Nortriptyline [2] 6, 226
889 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D08670 Venlafaxine [3] 6, 13, 46
890 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D10184 Vortioxetine [1] 6
891 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D11688 Ampreloxetine [2] 6, 17
892 SLC10A2 [1] Bile secretion D10796 Elobixibat [1] 6
893 SLC12A2 [3] Salivary secretion, Pancreatic secretion, Vibrio cholerae infection D00247 Bumetanide [2] 6, 158
894 SLC12A2 [3] Salivary secretion, Pancreatic secretion, Vibrio cholerae infection D00331 Furosemide [1] 6
895 SLC18A2 [3] Synaptic vesicle cycle, Serotonergic synapse, Parkinson disease D08575 Tetrabenazine [1] 8
896 SLC18A2 [3] Synaptic vesicle cycle, Serotonergic synapse, Parkinson disease D10675 Valbenazine [1] 8
897 SLC18A2 [3] Synaptic vesicle cycle, Serotonergic synapse, Parkinson disease D10701 Deutetrabenazine [1] 8
898 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A [13] 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226
899 SNAP25 [2] Synaptic vesicle cycle, Insulin secretion D02735 Botulinum toxin type B [4] 2, 6, 13, 51
900 SNCA [3] Alzheimer disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases D11420 Prasinezumab [1] 6
901 SOD1 [4] Peroxisome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases D11811 Tofersen [1] 2
902 SRC [42] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Rap1 signaling pathway, Chemokine signaling pathway, Mitophagy - animal, Endocytosis, Axon guidance, VEGF signaling pathway, Focal adhesion, Adherens junction, Tight junction, Gap junction, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, GABAergic synapse, Inflammatory mediator regulation of TRP channels, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Bacterial invasion of epithelial cells, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Yersinia infection, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Viral carcinogenesis, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Bladder cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09664 Saracatinib [3] 6, 89, 272
903 SRD5A2 [3] Steroid hormone biosynthesis, Metabolic pathways, Prostate cancer D00321 Finasteride [1] 6
904 ABCC8 [3] ABC transporters, Insulin secretion, Type II diabetes mellitus D00594 Repaglinide [3] 6, 21, 299
905 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
906 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
907 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
908 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
909 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
910 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
911 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
912 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
913 TUBB2A [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
914 UGCG [2] Sphingolipid metabolism, Metabolic pathways D11633 Venglustat [3] 6, 19, 67
915 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol [25] 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
916 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00299 Dihydrotachysterol [2] 6, 85
917 TRPV1 [2] Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00250 Capsaicin [5] 2, 6, 19, 86, 226
918 XDH [5] Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome D00224 Allopurinol [6] 6, 46, 57, 66, 96, 97
919 XDH [5] Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome D01206 Febuxostat [3] 2, 6, 13
920 CA2 [7] Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
921 CA4 [3] Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
922 CACNA1C [34] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
923 CACNA1C [34] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
924 CACNA1D [35] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
925 CACNA1D [35] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
926 CACNA1F [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
927 CACNA1F [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
928 CACNA1S [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00349 Isradipine [1] 6
929 CACNA1S [27] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
930 CACNA2D1 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
931 VKORC1 [3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D00564 Warfarin [13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
932 VKORC1 [3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D01280 Warfarin [13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
933 VKORC1 [3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D08682 Warfarin [13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
934 ALDH5A1 [3] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
935 TAS1R2 [2] Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame [5] 6, 13, 67, 86, 230
936 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
937 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
938 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
939 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
940 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
941 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
942 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
943 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
944 TUBB1 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
945 TAS1R3 [2] Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame [5] 6, 13, 67, 86, 230
946 CASP9 [14] Platinum drug resistance, PI3K-Akt signaling pathway, VEGF signaling pathway, Thyroid hormone signaling pathway, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Prostate cancer, Small cell lung cancer, Viral myocarditis D11195 Rimiducid [6] 19, 60, 65, 284, 285, 326
947 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00491 Paclitaxel [2] 46, 85
948 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D00570 Colchicine [7] 2, 42, 46, 56, 93, 210, 266
949 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D01068 Vinblastine [2] 34, 65
950 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D02197 Vincristine [4] 26, 34, 65, 331
951 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D05333 Paclitaxel [2] 46, 85
952 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08675 Vinblastine [2] 34, 65
953 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D08679 Vincristine [4] 26, 34, 65, 331
954 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D09587 Brentuximab vedotin [2] 49, 51
955 TUBB6 [6] Phagosome, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection D11595 Belantamab mafodotin [1] 28
956 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
957 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
958 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02008 Tadalafil [7] 6, 51, 75, 84, 86, 113, 210
959 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02229 Sildenafil [17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
960 PDE5A [3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08514 Sildenafil [17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
961 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
962 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00538 Zonisamide [1] 6
963 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
964 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00538 Zonisamide [1] 6
965 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
966 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00538 Zonisamide [1] 6
967 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
968 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05156 Nicotine [3] 6, 13, 84
969 CHRNA6 [3] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05157 Nicotine [3] 6, 13, 84
970 HTR3B [2] Serotonergic synapse, Taste transduction D00283 Clozapine [1] 6
971 HTR3B [2] Serotonergic synapse, Taste transduction D00456 Ondansetron [4] 6, 97, 107, 231
972 HTR3B [2] Serotonergic synapse, Taste transduction D00678 Ondansetron [4] 6, 97, 107, 231
973 HTR3B [2] Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
974 CACNA2D2 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
975 MS4A1 [1] Hematopoietic cell lineage D02994 Rituximab [49] 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
976 CACNA2D4 [7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin [5] 6, 13, 19, 70, 298
977 KEAP1 [3] Ubiquitin mediated proteolysis, Parkinson disease, Pathways in cancer D03846 Dimethyl fumarate [5] 13, 49, 51, 86, 296
978 SV2A [1] ECM-receptor interaction D00709 Levetiracetam [3] 6, 13, 307
979 NR1H4 [1] Bile secretion D00734 Ursodeoxycholic acid [14] 6, 8, 20, 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299